Takeaway

• The antibody-drug conjugate trastuzumab deruxtecan (the latter a topoisomerase inhibitor) reduces risk of progression by a striking 72% over trastuzumab emtansine in patients whose metastatic HER2 ⁺ breast cancer has progressed after treatment with front-line anti-HER2 antibodies and a taxane, according to the DESTINY-Breast03 trial.

Why this matters

• Findings...